Advertisement

Ads Placeholder
Loading...

exactEarth Ltd.

XCT.TOTSX
Technology
Software - Application
$3.10
$0.05(1.64%)
Canadian Market opens in 15h 24m

exactEarth Ltd. Fundamental Analysis

exactEarth Ltd. (XCT.TO) shows moderate financial fundamentals with a PE ratio of -13.27, profit margin of -26.71%, and ROE of 20.20%. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

ROE20.20%
PEG Ratio-0.13

Areas of Concern

Operating Margin-10.91%
We analyze XCT.TO's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 86.8/100 based on profitability, valuation, growth, and balance sheet metrics. The B+ grade reflects solid fundamentals with room for improvement in valuation or growth.

Fundamental Health Score

B+
86.8/100

We analyze XCT.TO's fundamental strength across five key dimensions:

Efficiency Score

Weak

XCT.TO struggles to generate sufficient returns from assets.

ROA > 10%
-25.25%

Valuation Score

Excellent

XCT.TO trades at attractive valuation levels.

PE < 25
-13.27
PEG Ratio < 2
-0.13

Growth Score

Weak

XCT.TO faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Excellent

XCT.TO maintains a strong and stable balance sheet.

Debt/Equity < 1
-4.24
Current Ratio > 1
1.47

Profitability Score

Weak

XCT.TO struggles to sustain strong margins.

ROE > 15%
20.20%
Net Margin ≥ 15%
-26.71%
Positive Free Cash Flow
N/A

Key Financial Metrics

Is XCT.TO Expensive or Cheap?

P/E Ratio

XCT.TO trades at -13.27 times earnings. This suggests potential undervaluation.

-13.27

PEG Ratio

When adjusting for growth, XCT.TO's PEG of -0.13 indicates potential undervaluation.

-0.13

Price to Book

The market values exactEarth Ltd. at -25.84 times its book value. This may indicate undervaluation.

-25.84

EV/EBITDA

Enterprise value stands at 1.60 times EBITDA. This is generally considered low.

1.60

How Well Does XCT.TO Make Money?

Net Profit Margin

For every $100 in sales, exactEarth Ltd. keeps $-26.71 as profit after all expenses.

-26.71%

Operating Margin

Core operations generate -10.91 in profit for every $100 in revenue, before interest and taxes.

-10.91%

ROE

Management delivers $20.20 in profit for every $100 of shareholder equity.

20.20%

ROA

exactEarth Ltd. generates $-25.25 in profit for every $100 in assets, demonstrating efficient asset deployment.

-25.25%

Following the Money - Real Cash Generation

FCF Per Share

Each share generates $-0.19 in free cash annually.

$-0.19

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-13.27

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.13

vs 25 benchmark

P/B Ratio

Price to book value ratio

-25.84

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.00

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-4.24

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.47

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

20.20

vs 25 benchmark

ROA

Return on assets percentage

-0.25

vs 25 benchmark

ROCE

Return on capital employed

-0.18

vs 25 benchmark

How XCT.TO Stacks Against Its Sector Peers

MetricXCT.TO ValueSector AveragePerformance
P/E Ratio-13.2734.22 Better (Cheaper)
ROE2020.16%1033.00% Excellent
Net Margin-26.71%-48116.00% (disorted) Weak
Debt/Equity-4.240.44 Strong (Low Leverage)
Current Ratio1.475.66 Neutral
ROA-25.25%-288969.00% (disorted) Weak

XCT.TO outperforms its industry in 3 out of 6 key metrics, particularly excelling in ROE, but lagging in Net Margin.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews exactEarth Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Growth, Innovation, High Beta

EPS CAGR

N/A

Industry Style: Growth, Innovation, High Beta

FCF CAGR

N/A

Industry Style: Growth, Innovation, High Beta

Fundamental Analysis FAQ